Skip to main content
Caplight Logo









Edgewood Oncology

Edgewood Oncology

Private
Brookline, MassachusettsHealthcare & Life Scienceshttps://www.edgewoodoncology.com/

Last Round

Series A

Mar 25, 2024

Total Funding Raised

$20M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Edgewood Oncology is a biotechnology company developing BTX-A51, a small molecule, multi-kinase inhibitor for patients with hematologic malignancies and genetically-defined solid tumors.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share

AI Layer

Non-AI

Keywords

oncology therapeuticssmall molecule drugmulti-kinase inhibitorclinical-stage biotechtargeted cancer therapyhematologic malignanciesblood cancersolid tumorsAcute Myeloid LeukemiaAMLoral cancer drugprecision oncologygenetically-defined tumorsCK1α inhibitorCDK7 inhibitorCDK9 inhibitorapoptosis inductionvirtual biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Edgewood Oncology Comparables

Compare Edgewood Oncology with similar companies based on industry and business-model similarity.

Edgewood Oncology comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
CasInvent Pharma
75%
Prelude Therapeutics
73%
Syros Pharmaceuticals Inc
71%

Edgewood Oncology Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMar 25, 2024

Key People

Founding team and executive leadership

David Cook

Chief Executive Officer

Executive Team

Edgewood Oncology Investors

Notable investors and investment history

Edgewood Oncology investors
InvestorRounds
Alta PartnersSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 41% MoM, from 1.1K to 1.5K.

  • Jun 21, 2026

    Monthly visitors grew 68% MoM.

Edgewood Oncology Filings

Explore SEC and related filing metadata, where available.

Edgewood Oncology filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Edgewood Oncology's valuation, stock price, and market status.

Is Edgewood Oncology a public or private company?

Edgewood Oncology is a private company.

What is the current stock price of Edgewood Oncology?

Edgewood Oncology is a private company with no public stock price. No recent secondary market data is available.

How much is Edgewood Oncology worth (valuation)?

Valuation information for Edgewood Oncology is not publicly available.

Can I buy Edgewood Oncology stock?

Edgewood Oncology shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was Edgewood Oncology's last funding round?

Edgewood Oncology's most recent funding round was Series A on March 25, 2024.

Who are the main investors in Edgewood Oncology?

Key investors in Edgewood Oncology include Alta Partners.

Will Edgewood Oncology IPO soon?

No public IPO plans have been announced for Edgewood Oncology.

How can I track Edgewood Oncology secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Edgewood Oncology's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersBrookline, Massachusetts
Employee Range2
Year Founded2023
Last FundingMar 25, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?